Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910934 | 0.80 | ESR1 (0.56) | TDP1L3MBTL1MEN1CYP1A2CYP2C19 | |
| SCHEMBL308466 | 0.80 | CCR1 (0.41) | ALDH1A1CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL28865099 | 0.79 | CCR1 (0.40) | ALDH1A1CYP2C19KMT2A | |
| SCHEMBL8443965 | 0.77 | ESR1 (0.56) | TDP1L3MBTL1MEN1CYP1A2CYP2C19 | |
| SCHEMBL3040144 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KMT2A | |
| SCHEMBL7619906 | 0.73 | ALDH1A1 (0.51) | ALDH1A1GAAHPGDTDP1L3MBTL1 | |
| SCHEMBL11094158 | 0.72 | HTR1A (0.47) | HTR1A | |
| SCHEMBL15326986 | 0.72 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDTDP1KMT2A | |
| SCHEMBL4651613 | 0.71 | ESR1 (0.58) | HTR1A | |
| SCHEMBL4967468 | 0.71 | TLR8 (0.50) | ALDH1A1TDP1L3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10219730-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20160296147-A1 | Redox Polymers | THERASENSE, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9320467-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140364710-A1 | Redox Polymers | THERASENSE, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828204-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8795490-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8637194-B2 | Bio-nano power cells and their uses | BIO-NANO POWER, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130330293-A1 | BIO-NANO POWER CELLS AND THEIR USES | BIO-NANO POWER (US) | 2013-12-12 | — | — | US | disclosed |
| US-8512534-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8168052-B2 | Transition metal complexes with bidentate ligand having an imidazole ring | ABBOTT DIABETES CARE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8092662-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110306111-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110303538-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110303537-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20100288634-A1 | Transition Metal Complexes with Bidentate Ligand Having an Imidazole Ring | ABBOTT DIABETES CARE INC. | 2010-11-18 | — | — | US | disclosed |
| EP-1230248-B1 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE INC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-6605200-B1 | Charge transfer compounds comprising polymers such as polyvinylpyridine and/or copolymers coupled to osmium compounds, used as biosensors in redox systems | THERASENSE, INC. | 2003-08-12 | — | — | US | disclosed |
| EP-1230248-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | Therasense, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036660-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130330293-A1 | BIO-NANO POWER CELLS AND THEIR USES | GPX4, GPX1, LPO | ALDH1A1 521/4885GAA 3418/4885HPGD 735/4885 |
| US-10219730-B2 | Redox polymers | PPOX, OTC, ME3 | ALDH1A1 1292/4885GAA 965/4885HPGD 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.